{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:17:41Z","timestamp":1793215061660,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.ajkd.2026.02.639","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:45:16Z","timestamp":1778125516000},"page":"18-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)"],"prefix":"10.1053","volume":"88","author":[{"given":"Isabelle","family":"Ayoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Coppock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Wadhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-8555","authenticated-orcid":false,"given":"Timothy","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4S","key":"10.1053\/j.ajkd.2026.02.639_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2026.02.639_bib3","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2026.02.639_bib6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2215\/CJN.16021219","article-title":"External validation of the International IgA Nephropathy Prediction Tool","volume":"15","author":"Zhang","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2026.02.639_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-Kidney trial","volume":"12","author":"Staplin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10417","key":"10.1053\/j.ajkd.2026.02.639_bib11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2026.02.639_bib12","article-title":"WCN24-773 Sparsentan as first-line treatment of incident patients with IgA nephropathy: preliminary findings from the SPARTAN trial","volume":"9","author":"Cheung","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"10405","key":"10.1053\/j.ajkd.2026.02.639_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2026.02.639_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2026.02.639_bib15","author":"Jerling"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib16","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.2016091043","article-title":"Galactosylation of IgA1 is associated with common variation in C1GALT1","volume":"28","author":"Gale","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2215\/CJN.0000000707","article-title":"Proteinuria trajectory and disease progression in children and adults with IgA nephropathy\/vasculitis","volume":"20","author":"Glenn","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.02.639_bib18","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.ekir.2022.09.017","article-title":"One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy","volume":"7","author":"Lafayette","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2026.02.639_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47393-1","article-title":"An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression","volume":"13","author":"Obri\u015fc\u0103","year":"2023","journal-title":"Sci Rep"},{"issue":"26","key":"10.1053\/j.ajkd.2026.02.639_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA nephropathy","volume":"99","author":"Ismail","year":"2020","journal-title":"Medicine"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.02.639_bib22","first-page":"i6","article-title":"How should we target and reduce the production of pathogenic IgA in IgAN?","volume":"41","author":"Cheung","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.02.639_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.02.639_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"10S","key":"10.1053\/j.ajkd.2026.02.639_bib27","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20253s04myx7","article-title":"Efficacy and safety of povetacicept in patients with IgAN and primary membranous nephropathy (pMN) at 48 weeks of treatment: the RUBY-3 study","volume":"36","author":"Tumlin","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib28","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1681\/ASN.2006121343","article-title":"Complement C5 mediates experimental tubulointerstitial fibrosis","volume":"18","author":"Boor","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2026.02.639_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2369-12-64","article-title":"Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function","volume":"12","author":"Onda","year":"2011","journal-title":"BMC Nephrol"},{"issue":"9156","key":"10.1053\/j.ajkd.2026.02.639_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2026.02.639_bib34","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2026.02.639_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MNH.0000000000000881","article-title":"An update on corticosteroid treatment for IgA nephropathy","volume":"32","author":"Ghaddar","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib36","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ekir.2024.03.032","article-title":"The efficacy and safety of reduced-dose oral methylprednisolone in high-risk immunoglobulin A nephropathy","volume":"9","author":"Kim","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2026.02.639_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2026.02.639_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib41","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2026.02.639_bib42","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2026.02.639_bib45","first-page":"967","article-title":"Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study","volume":"35","author":"Hotta","year":"1993","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"8","key":"10.1053\/j.ajkd.2026.02.639_bib46","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2026.02.639_bib47","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00467-006-0272-6","article-title":"Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy","volume":"21","author":"Kawasaki","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.02.639_bib48","first-page":"CD003962","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Reid","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1053\/j.ajkd.2026.02.639_bib49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/0886022X.2015.1128251","article-title":"The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial","volume":"38","author":"Yang","year":"2016","journal-title":"Ren Fail"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4772","article-title":"Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy","volume":"2","author":"Hirano","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45514-4","article-title":"Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy","volume":"13","author":"Kawamura","year":"2023","journal-title":"Sci Rep"},{"issue":"4S","key":"10.1053\/j.ajkd.2026.02.639_bib52","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2026.02.639_bib53","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib54","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"issue":"3S","key":"10.1053\/j.ajkd.2026.02.639_bib55","first-page":"S71","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2026.02.639_bib56","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis","volume":"40","author":"Vivarelli","year":"2025","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib57","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00467-007-0726-5","article-title":"Improved renal survival in Japanese children with IgA nephropathy","volume":"23","author":"Yata","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib58","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2026.02.639_bib59","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00467-024-06361-1","article-title":"Are children with IgA nephropathy different from adult patients?","volume":"39","author":"Su","year":"2024","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.02.639_bib60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ekir.2018.03.013","article-title":"Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features","volume":"3","author":"Cambier","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.ajkd.2026.02.639_bib61","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2026.02.639_bib62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2215\/CJN.01120905","article-title":"Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial","volume":"1","author":"Yoshikawa","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"10","author":"Yoshikawa","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib64","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib65","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00467-016-3390-9","article-title":"Biomarkers and targeted new therapies for IgA nephropathy","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2026.02.639_bib66","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1093\/ndt\/gfn014","article-title":"IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes","volume":"23","author":"Haas","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib67","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ped.13074","article-title":"Long-term follow up of pediatric immunoglobulin A nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy","volume":"59","author":"Kawasaki","year":"2017","journal-title":"Pediatr Int"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ndt\/gfq387","article-title":"Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination\/prednisolone therapy","volume":"26","author":"Shima","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib70","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/14.5.1097","article-title":"Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy\u2014is it relevant for adult patients?","volume":"14","author":"Yoshikawa","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2026.02.639_bib71","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.02.639_bib72","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1681\/ASN.2012101017","article-title":"Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.02.639_bib73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00467-012-2294-6","article-title":"Spontaneous remission in children with IgA nephropathy","volume":"28","author":"Shima","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.02.639_bib74","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1053\/j.ajkd.2026.02.639_bib75","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.2005.046300","article-title":"EULAR\/PReS endorsed consensus criteria for the classification of childhood vasculitides","volume":"65","author":"Ozen","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib76","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara. 2008. Part II: Final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.02.639_bib77","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","article-title":"Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults","volume":"47","author":"Coppo","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib78","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.ASN.0000013883.99976.22","article-title":"Henoch-Sch\u00f6nlein purpura in adults: outcome and prognostic factors","volume":"13","author":"Pillebout","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.02.639_bib79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/qjmed\/hcl034","article-title":"Henoch Sch\u00f6nlein purpura with nephritis in adults: adverse prognostic indicators in a UK population","volume":"99","author":"Shrestha","year":"2006","journal-title":"QJM"},{"issue":"4","key":"10.1053\/j.ajkd.2026.02.639_bib80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2215\/CJN.0000000000000398","article-title":"Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis","volume":"19","author":"Barbour","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.02.639_bib81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.ajkd.2011.12.015","article-title":"Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Sch\u00f6nlein purpura in adults: a case series","volume":"59","author":"Augusto","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2026.02.639_bib82","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/adc.2008.141820","article-title":"Prevention and treatment of renal disease in Henoch-Sch\u00f6nlein purpura: a systematic review","volume":"94","author":"Chartapisak","year":"2009","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1053\/j.ajkd.2026.02.639_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005128.pub2","article-title":"Interventions for preventing and treating kidney disease in Henoch-Sch\u00f6nlein purpura (HSP)","author":"Chartapisak","year":"2009","journal-title":"Cochrane Database Syst Rev"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:30:29Z","timestamp":1782513029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626008425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0272638626008425"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.02.639","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.02.639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}